SCHOTT expands India footprint with first local production of syringe and cartridge glass tubing

Schott

SCHOTT AG, the German specialty glass giant, has launched local production of high-precision syringe and cartridge glass tubing in India, marking a strategic leap in the country’s pharmaceutical packaging capabilities.

The expansion at its Jambusar facility in Gujarat positions SCHOTT as Asia’s largest producer of syringe and cartridge glass tubing.

The move comes amid surging global demand for GLP-1-based injectables like semaglutide, used in diabetes and weight management.

“This strategic expansion marks a significant milestone in our journey to support pharmaceutical packaging capabilities in India,” said Sundeep Prabhu, Senior VP of Sales & Marketing at SCHOTT Glass India.

The new production line is a direct technology transfer from SCHOTT’s German operations and aligns with India’s ‘Make in India’ initiative. It also reinforces the country’s pharmaceutical self-reliance at a time when global supply chains are under scrutiny.

SCHOTT’s FIOLAX Type I borosilicate glass tubing is known for its tight geometric tolerances, especially in inner diameter control—critical for ensuring plunger tightness and smooth drug delivery in prefilled syringes and cartridges.

“We’re ensuring a stable and consistent supply chain for critical drug delivery systems,” said Pawan Kumar Shukla, President & MD of SCHOTT Glass India. “With our perfeXion quality system analyzing 100,000 data points per minute, we aim to achieve zero-defect manufacturing.”

India was chosen for its fast-growing pharma industry, skilled workforce, and favorable regulatory climate. The Jambusar site is already SCHOTT’s second-largest pharmaceutical tubing facility globally.

The GLP-1 segment is projected to grow at a compound annual growth rate (CAGR) of 33%, driven by rising demand for injectable therapies. SCHOTT’s expansion enables it to serve this market end-to-end—from vials and ampoules to syringes and cartridges.